Monday, 23 December 2024
  
Login

Australia's most trusted
source of pharma news

Monday, 23 December 2024
Pif Xmas
Pif Xmas
PBAC says yes to almost everyone

Much of the industry has ended 2024 on a high with the PBAC recommending almost every submission considered at the hefty November meeting - but the battle now is to convert the wins into PBS listings as quickly as possible in the new year.

Big brands score expanded listings
But most included in existing Risk Sharing Agreements
TODAY
2024: A Year of Indecision?
A year characterised the one big thing that didn't happen
TODAY
Three new drugs pass TGA muster
Includes two PBS listing hopefuls and a Botox alternative
TODAY Approvals Action
Ascott
Ascott
Who got booted to the May meet?
PBAC unveils 16 drugs on the additional meeting agenda
19 December
Company tops Rotten Tomato list
One Big Pharma recognised for a slip up, another for best behaviour
19 December
Best company Christmas gift is...
Survey of pharma professionals reveals what they really want
19 December
First out the door in '25?
Drugs line up for the first PBS listings of the New Year
18 December
PiF Jobs
PiF Jobs
Latest Jobs
Best pharma one-liners of 2024
Heart-felt, inspired, funny... the voices of Aussie pharma
20 December
First wholesaler agreement signed
Govt inks five-year $4.2B medicine distribution deal
20 December
It's a wrap: Top 10 stories of 2024
The most popular Pharma in Focus stories of the year
20 December
Meet Merck's new Medical Director
Joins the company following a stellar career at MSD
20 December
What it took to keep Dupixent listed
Behind the deal that required Butler to 'move heaven and earth'
20 December
Pharma's 'C-bomb' problem
The difference between content and quality communication
20 December
All eyes on this PBAC decision...
How funding calls for a J&J drug captured public attention
19 December
Novo holds off generic competition
Court ruling confirms patent protection for another year
19 December
Mid-Year $3.7 billion PBS refigure
Why predicted PBS spending has surged since the May Budget
19 December
He's back: Ex-GM wins CEO role
Bringing decades of leadership and marketing experience
18 December
No relief for Ozempic supply issues
Novo Nordisk updates TGA on 2025 outlook
18 December
Mega-buy clears regulatory hurdles
Despite widespread opposition, Novo deal is a goer
18 December
PBS review finds admin lacking
However, cost management is 'largely effective'
18 December
Medicine an election 'sleeper' issue
Poll of Aussie voters exposes discontent with healthcare
18 December
PiF advertise
PiF advertise
Welcome to Pharma in Focus

Please log in to read.

Hi

Our old access system is being retired.

Please create a password and click 'Log in' for ongoing access.

Hi

Please choose a password to secure your access to Pharma in Focus (minimum 8 characters).

Hi

You're here because you requested to reset your password.

Please choose a new password (minimum 8 characters).

To search the News Archive you need to be logged in.

 

You can choose not to do this now but after November 30, a password will be required.

To learn more about the new-look Pharma in Focus click here.